B+
Bull case
25%
Probability
Target price
$90.00
Analysis reference price unavailable
Analysis 2026-09-22 · RankAlpha Sentiment Codex
TPB
Turning Point BrandsDNYSE / Food Beverage & Tobacco
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$65.00
Analysis reference price unavailable
Analysis 2026-09-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-09-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-22
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.2
Score
AI commentary
The September 21 leadership announcement and lower EBITDA ceiling shifted the setup from a growth-led rerating toward cautious monitoring. The $61.31 anchor is dated the announcement day, suggesting some immediate reaction may already be reflected, but the packet does not quantify the move. Social coverage, options skew, short interest, employee sentiment and reliable post-event analyst revisions are unavailable; zero values in the sentiment object denote unavailable inputs rather than neutral readings.
RankAlpha Sentiment Codex - 2026-09-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-01eventCEO transition and reduced EBITDA ceilingMedium impact
David Glazek becomes CEO on October 1 after Graham Purdy's resignation for personal reasons. TPB reaffirmed 2026 Modern Oral sales guidance but tightened adjusted EBITDA guidance to $70 million-$80 million from $70 million-$90 million, citing delayed onshoring benefits and prolonged higher freight costs. [#8-K-2026-09-21]
2026-12-31catalystInvestment and regulatory costs pressure marginsHigh impact
Q2 adjusted EBITDA declined sharply as TPB increased sales, marketing and retail investment and faced Zig-Zag weakness. The latest 10-Q also disclosed $3.2 million of quarterly PMTA costs, while prolonged freight costs and delayed onshoring benefits constrain near-term margin recovery. [#PR-EARNINGS-2026-08-09][#10-Q-2026-08-04][#8-K-2026-09-21]
2027-12-31catalystModern Oral distribution and manufacturing scale-upHigh impact
TPB reaffirmed 2026 Modern Oral gross-sales guidance of $330 million-$350 million and net-sales guidance of $260 million-$270 million. Q2 context showed strong Modern Oral growth, while retail resets and planned domestic manufacturing provide longer-term operating leverage; the company now assumes no onshoring margin benefit until 2027. [#8-K-2026-09-21][#PR-EARNINGS-2026-08-09]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-22 • Updated nightlySource: Internal modelMethodology